Clinical effect and outcome analysis of icotinib and gefitinib targeted therapy for advanced non-small cell lung cancer
Objective To analyze the clinical effect of icotinib and gefitinib targeted therapy for advanced non-small cell lung cancer(NSCLC).Methods A total of 80 patients with advanced NSCLC admitted in our hospital from April 2018 to April 2021 were selected as the research objects.According to the random number table method,the patients were divided into control group(n=40,gefitinib)and study group(n=40,icotinib).The therapeutic effect,serum index,immune function,quality of life,treatment outcome and adverse reactions were compared between the two groups.Results There was no significant difference in disease control rate between the two groups(P>0.05).After treatment,the levels of carcinoembryonic antigen(CEA),cancer antigen 125(CA125),neurocadherin mRNA,angiopoietin-2(Ang-2)and vascular endothelial growth factor(VEGF)in the two groups decreased,and those in the study group were lower than the control group(P<0.05).After treatment,the CD3+,CD4+and CD4+/CD8+in the study group were higher than those in the control group,and the CD8+was lower than that in the control group(P<0.05).After treatment,the scores of each dimension of European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30(EORTC QLQ-C30)in the study group were higher than those in the control group(P<0.05).The mortality rate of the study group was lower than that of the control group(P<0.05);there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Icotinib targeted therapy for advanced NSCLC has a clinical effect that is not inferior to gefitinib,it can improve serum indexes,improve immune function,prolong survival time and improve quality of life.
万方数据
维普
